McCain T W, Dunagan D P, Chin R, Oaks T, Harkness B A, Haponik E F
Department of Medicine, Section on Pulmonary and Critical Care Medicine, Wake Forest University Medical School, Winston-Salem, NC 27157-1054, USA.
Chest. 2000 Dec;118(6):1610-5. doi: 10.1378/chest.118.6.1610.
Positron emission tomography (PET) can contribute to diagnosing and staging lung cancer, but it has not been determined whether this information influences patient care.
We reviewed the effects of thoracic PET scan results during an 11-month period. For each patient, physicians ordering these scans reported how PET specifically altered management, and graded the ease of interpretation and overall usefulness of PET on a 5-point scale. In addition, to appraise general attitudes about PET, we surveyed 488 national American Thoracic Society (ATS) members and 44 physicians at our comprehensive cancer center.
One hundred twenty-six questionnaires regarding patients were mailed to 37 ordering physicians, and 98 responses (78%) were returned, primarily by cardiothoracic surgeons (35%) and pulmonologists (47%). Respondents reported that PET provided new information in 83 patients (85%) and altered patient management in 64 cases (65%). Major effects on management included decisions regarding biopsy (n = 16), surgery (n = 16), and palliative treatment (n = 16). Chest clinicians found PET to be more helpful (4.4 vs 3.9, p = 0.007) and easier to interpret (4.2 vs 3.7, p = 0.025) than other specialists. Among 139 ATS members (28%) responding to the general survey, 51 members (39%) had access to PET. PET was more frequently available to university-based (49%) than community-based (27%) physicians (p = 0.016). The majority of physicians without current access to PET (69%) indicated that they would like to have it available. ATS members with access to PET reported that PET results generally affect decisions regarding biopsy or surgery most often, but found the procedure less helpful than physicians at our center (2.77 vs 3. 56, p = 0.003) and ordered it less often for lung cancer staging (60% vs 96%, p = 0.002).
PET scanning is useful in the management of patients with suspected thoracic malignancies, but impressions about its roles vary, with PET regarded more highly where, as at our center, it is used more often. Whether PET alters patient outcomes requires investigation.
正电子发射断层扫描(PET)有助于肺癌的诊断和分期,但尚未确定该信息是否会影响患者的治疗。
我们回顾了11个月期间胸部PET扫描结果的影响。对于每位患者,开具这些扫描检查的医生报告了PET如何具体改变治疗方案,并按5分制对PET的解读难易程度和总体有用性进行评分。此外,为了评估对PET的总体态度,我们对488名美国胸科学会(ATS)成员和我们综合癌症中心的44名医生进行了调查。
向37位开具检查单的医生邮寄了126份关于患者的问卷,共收到98份回复(78%),主要来自心胸外科医生(35%)和肺科医生(47%)。受访者报告称,PET为83名患者(85%)提供了新信息,64例(65%)改变了患者的治疗方案。对治疗方案的主要影响包括活检(n = 16)、手术(n = 16)和姑息治疗(n = 16)方面的决策。胸部疾病临床医生发现PET比其他专科医生更有帮助(4.4比3.9,p = 0.007)且更容易解读(4.2比3.7,p = 0.025)。在139名回复一般调查的ATS成员(28%)中,51名成员(39%)可以使用PET。与社区医生(27%)相比,大学附属医院医生(49%)更常能使用PET(p = 0.016)。大多数目前无法使用PET的医生(69%)表示希望能够使用。可以使用PET的ATS成员报告称,PET结果通常最常影响活检或手术的决策,但他们发现该检查不如我们中心的医生认为的那么有帮助(2.77比3.56,p = 0.003),且用于肺癌分期的频率较低(60%比96%,p = 0.002)。
PET扫描对疑似胸部恶性肿瘤患者的治疗有帮助,但对其作用的看法各不相同,在像我们中心这样更常使用PET的地方,其受认可度更高。PET是否会改变患者的治疗结果尚需进一步研究。